All In Biotech

Drug Trial Radar · NCT03004469

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness

Last checked: Nov 19, 2026Latest source record: Jun 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 458 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

458

Actual

Start

Aug 2, 2016

Primary completion

Mar 5, 2018

Study completion Mar 5, 2018

Sponsor

Lead sponsor
Polichem S.A.Industry
Sponsor type
Industry
First posted
Dec 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.

Conditions

  • Alopecia, Androgenetic

Interventions

  • P-3074Drug

  • FinasterideDrug

  • P-3074 VehicleDrug

  • Finasteride PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24Time frame: Baseline and Week 24

Locations

46 sites in 5 countries. Site status is shown where the registry gives one.

  • Site #102

    Brussels, Belgium

  • Site #103

    Brussels, Belgium

  • Site #104

    Brussels, Belgium

  • Site #101

    Ghent, Belgium

  • Site #211

    Augsburg, Germany

  • Site #202

    Berlin, Germany

  • Site #212

    Berlin, Germany

  • Site #216

    Bochum, Germany

  • Site #210

    Dresden, Germany

  • Site #217

    Dresden, Germany

  • Site #221

    Dresden, Germany

  • Site #203

    Düsseldorf, Germany

  • Site #204

    Freiburg im Breisgau, Germany

  • Site #206

    Hamburg, Germany

  • Site #214

    Hamburg, Germany

  • Site #218

    Hamburg, Germany

  • Site #213

    Hanover, Germany

  • Site #215

    Karlsruhe, Germany

  • Site #220

    Lübeck, Germany

  • Site #208

    Münster, Germany

  • Site #219

    Potsdam, Germany

  • Site #209

    Schwerin, Germany

  • Site #201

    Wuppertal, Germany

  • Site #303

    Budapest, Hungary

  • Site #309

    Budapest, Hungary

  • Site #302

    Debrecen, Hungary

  • Site #308

    Sátoraljaújhely, Hungary

  • Site #301

    Szolnok, Hungary

  • Site #307

    Szombathely, Hungary

  • Site #401

    Chelyabinsk, Russia

  • Site #402

    Moscow, Russia

  • Site #407

    Moscow, Russia

  • Site #411

    Moscow, Russia

  • Site #409

    Rostov-on-Don, Russia

  • Site #403

    Ryazan, Russia

  • Site #406

    Saint Petersburg, Russia

  • Site #408

    Saint Petersburg, Russia

  • Site #410

    Yaroslavl, Russia

  • Site #503

    Alicante, Spain

  • Site #505

    Barakaldo, Spain

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.